Immuneering

Yahoo Finance • 2 days ago

Biggest stock movers Thursday: INTC, RIG, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures ticked higher in the premarket hours of Thursday as investors awaited the release of key jobs data, hoping for signals on labor market s... Full story

Yahoo Finance • 2 days ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,91... Full story

Yahoo Finance • 2 days ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Cla... Full story

Yahoo Finance • 2 days ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal tria... Full story

Yahoo Finance • 16 days ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical... Full story

Yahoo Finance • 29 days ago

Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial

Eli Lilly announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's oncology portfolio. Meanwhile, the Phase 3 ATTAI... Full story

Yahoo Finance • last month

Immuneering closes $25 million private placement to accredited investors

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), whose stock has surged over 170% year-to-date according to InvestingPro data, announced Tuesday it has closed its previously announced private placement, raising approximately $25 m... Full story

Yahoo Finance • last month

Immuneering Announces Closing of $25 Million Private Placement

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private place... Full story

Yahoo Finance • last month

TD Cowen reiterates Buy rating on Eli Lilly stock after Phase III data

Investing.com - TD Cowen has reiterated a Buy rating and $960.00 price target on Eli Lilly (NYSE:LLY), a prominent player in the pharmaceuticals industry with a market cap of $652 billion, following the company’s release of Phase III trial... Full story

Yahoo Finance • last month

Immuneering stock soars on clinical supply deal with Eli Lilly

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor,... Full story

Yahoo Finance • last month

Immuneering signs supply deal with Lilly to test atebimetinib plus olomorasib

[Scientist, doctor or technician doing a drug trial, test or experiment while working in a lab, science facility or hospital. One medical researcher, expert or professsional making a discovery at work] Sean Anthony Eddy Immuneering (NASDA... Full story

Yahoo Finance • last month

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Immuneering Corporation - Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering... Full story

Yahoo Finance • last month

Top stock movements in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMEN... Full story

Yahoo Finance • last month

Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT PTIX [https://www.char... Full story

Yahoo Finance • last month

There are notable gap-ups and gap-downs in today's session.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT APM [https://www.chartmill.com/stoc... Full story

Yahoo Finance • last month

Immuneering Announces $25 Million Private Placement

CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purc... Full story

Yahoo Finance • last month

Curious about the stocks that are showing activity after the closing bell on Wednesday?

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER... Full story

Yahoo Finance • last month

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 mont... Full story

Yahoo Finance • 3 months ago

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock

Immuneering Corp (NASDAQ:IMRX) Chief People Officer Leah R. Neufeld reported purchasing 700 shares of Class A Common Stock on July 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought a... Full story

Yahoo Finance • 3 months ago

Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data

Investing.com - Jefferies raised its price target on Immuneering Corporation (NASDAQ:IMRX) to $3.50 from $1.50 on Wednesday, while maintaining a Hold rating on the stock. For comprehensive analysis of biotech stocks like IMRX, including... Full story